Cytomos Platform Enabled Real-Time CAR T Quality Analysis
A new cell intelligence platform detected manufacturing divergence two days faster than standard flow cytometry methods.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe new diagnostic technologies will make life-saving medical treatments more affordable for patients?
Cytomos has developed the AuraCyt platform, which uses ultra-wideband dielectric spectroscopy to monitor CAR T-cell manufacturing. In a recent case study, the system identified distinct signatures between transduced and non-transduced cell populations by the fourth day of an eight-day workflow.
Why it matters
CAR T manufacturing currently faces significant hurdles from donor variability and limited analytical tools. Moving from retrospective quality control to predictive monitoring could improve yield and consistency in the $6 billion global CAR T therapy market.
The AuraCyt platform generates 507 parameters per cell using 200 measured frequencies. This high-dimensional data allows the system to characterize cellular states without requiring the chemical labels often necessary for traditional analysis.
The players
Cytomos
A developer of cell analysis hardware focused on transforming bio-manufacturing through high-dimensional dielectric sensing.
The details
AuraCyt uses ultra-wideband dielectric spectroscopy — a method that measures how different biological structures interact with varied electromagnetic frequencies — to profile single cells. By analyzing the frequency-dependent electrical behavior of these structures, the platform creates digital fingerprints for each cell. This allows it to distinguish between successfully transduced cells, which have been genetically modified to recognize cancer, and non-transduced populations based on physical state changes rather than biological staining.
Timeline
Day 0: Baseline analysis of donor T cells was performed.
Day 4: AuraCyt detected divergence in cell populations.
Day 6: Flow cytometry confirmed CAR-CD34 expression.
Day 8: The manufacturing workflow study concluded.
The Tech Race
As the industry matures beyond the seven current FDA-approved CAR T therapies, the race has shifted toward optimizing production efficiency. Cytomos is positioning its platform to compete against conventional flow cytometry by offering predictive control over manufacturing for the $6 billion market.
The AuraCyt platform aims to replace slower retrospective quality checks with real-time predictive monitoring in professional biomanufacturing settings. Lab managers and researchers in the immunotherapy space can look for future deployments that move away from reliance on chemical markers.
The takeaway
Cytomos has demonstrated that predictive analysis can shorten the time required to assess CAR T manufacturing progress. Industry stakeholders should watch for future performance benchmarks comparing this spectroscopic approach against existing standards in larger commercial batches.
Further reading
Explore the latest developments in cell manufacturing and engineering in our Biotech section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Do you believe new diagnostic technologies will make life-saving medical treatments more affordable for patients?
